Clinical Trials Logo

Infertility Unexplained clinical trials

View clinical trials related to Infertility Unexplained.

Filter by:

NCT ID: NCT05670795 Recruiting - Clinical trials for Infertility Unexplained

Comparison of Recombinant Follicle Stimulating Hormone and the Combination of Recombinant Follicle Stimulating Hormone With Clomiphene Citrate in Stimulated Intrauterine Insemination Cycles

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The aim of study is to evaluate the results of two different protocols for ovulation induction during IUI cycles. All patients undergo IUI cycles are randomly divided in to two groups. the first group is recombinant follicle stimulating hormone and the second group is the combination of recombinant follicle stimulating hormone with clomiphene citrate.

NCT ID: NCT05599724 Recruiting - Infertility Clinical Trials

PMA-FERTITHEQUE Biocollection

FERTITHEQUE
Start date: November 11, 2022
Phase:
Study type: Observational [Patient Registry]

Creation of a patient library in Medically Assisted Procreation to allow the implementation of further research with the following objectives: - To identify new relevant biomarkers in patients who will carry a pregnancy to term - To better specify or identify new infertility risk factors - To identify new relevant biomarkers in patients with reduced ovarian reserve Four consultations are planned with biological et clinical collection.

NCT ID: NCT05506722 Recruiting - Infertility, Male Clinical Trials

Using of Testes Shocker in Improving the Spermatogenesis and Sperms Activity

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Infertility was reported in approximately 15% of all heterozygous couples, with male factor accounting for nearly half the cases. This typically occurs due to low sperm production, sperm dysfunction, and sperm delivery obstruction. Etiology of male infertility can be attributed to many factors including acute or chronic illness, accidents, and lifestyle choices.

NCT ID: NCT05390606 Terminated - Infertility Clinical Trials

Effects of Flourish HEC and BioGenesis to Improve Conception

Start date: June 15, 2022
Phase: Phase 1
Study type: Interventional

This study intends to address whether improving the vaginal microbiome can help couples increase chances of conceiving.

NCT ID: NCT05190250 Completed - Infertility, Female Clinical Trials

Pro-inflammatory Cytokines and Implantation Process in Women With Primary Idiopathic Infertility

Start date: November 1, 2017
Phase:
Study type: Observational

Infertility is a common, worldwide problem. In about 20% of couples, the causative agent of infertility cannot be identified after routine diagnostic tests. One of the causes of idiopathic infertility may be implantation disorders. Implantation can take place at a strictly defined moment in the menstrual cycle, when the capacity of the blastocyst to implant is overlapped with readiness for its acceptance by the endometrium, the so-called endometrial receptivity.The time interval in which the endometrium exhibits this property is called the implantation window. The acquisition of receptivity by the endometrium is reflected in cellular and structural changes.The changes taking place at the cellular and molecular levels within the endometrium are compared to processes such as wound healing and degradation of the matrix during the neoplastic process.In considering the role of local inflammation in fertility, it is essential to distinguish between acute and chronic inflammation of moderate or low intensity.The profile of the molecules seen in a given inflammation depends on the severity, duration and mechanisms involved in the inflammation process, as well as the ability of the body's immune system to respond and adapt.IL-18 is a pro-inflammatory cytokine that mediates a type 1 cellular response. In the context of fertilization, IL-18 is a bivalent cytokine. Outside of the implantation window, IL-18 acts as an IFN-gamma inducer and is seen as a detrimental factor in the implantation process. During the implantation window, IL-18 becomes one of the main factors involved in the proper preparation of the spiral arteries. Histamine meets all the criteria of an inflammatory mediator. Histamine expression is also expressed in the endometrium, where it plays the role of a paracrine messenger during embryo decision-making and implantation. Adequate glucose uptake and metabolism are essential for the proper differentiation of the uterine endometrium towards a receptive state that allows the implantation of the embryo. The best described and most abundant glucose transporter in the endometrial stroma is GLUT1. However, there are no data on the role of GLUT4 in undetermined infertility. GLUT4 is one of the better studied transporters because of its major role in whole body glucose homeostasis and the pathogenesis of type II diabetes. Aims:1. Analysis of the level of interleukin 18 and histamine as molecules with a postulated role in the implantation process in the receptive endometrium in women with primary infertility of unknown etiology and comparing it to the group of women with naturally conceived offspring. 2. Assessment of the correlation of the levels of interleukin 18 and histamine in the receptive endometrium and in the blood as an attempt to find a diagnostic useful marker of receptivity. 3. Analysis of GLUT4 level in the receptive endometrium between two groups. Materials and Methods: Patients recruited from among women hospitalized at the CMUJ Gynecological Endocrinology Clinic for hormonal diagnostics. 1. The patient's visit during the implantation window (appropriate time of the cycle determined on the basis of ultrasound ovulation monitoring) 2. Endometrial aspiration biopsy, venous blood collection (5 ml). Preparation of material. 3. Analysis of the collected material.

NCT ID: NCT05080569 Not yet recruiting - Pregnancy Related Clinical Trials

Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment

LUMO
Start date: December 2022
Phase: Phase 4
Study type: Interventional

The LUMO study is a multicenter, randomized controlled trial that evaluates the effectivity of luteal phase support in MOH/IUI treatment.

NCT ID: NCT04945265 Not yet recruiting - Infertility Clinical Trials

Effects of Age and Infertility on Ovarian Granulosa Cell Function

Start date: July 2021
Phase:
Study type: Observational

Infertility is a life changing disorder, affecting 1 in 7 couples within the UK. Treatment options pose a significant cost burden to both the NHS and patient when NHS-funded treatment options are exhausted. This highlights the need for refinements in clinical management strategies for this patient group. Although there have been advancements in assisted reproductive technologies, the success rates of techniques such as in vitro fertilization (IVF) remain low. Surprisingly, the IVF hormonal regimens used by most assisted conception units fail to take account of patient age, ovarian reserve or cause of infertility when deciding on treatment regimen, with a 'one size fits all' approach to treatment. The investigators propose that age and cause of infertility modify the functions and environment provided by the cells (granulosa cells) that support egg (oocyte) growth and development and understanding these changes will allow for a more personalised approach to IVF treatment regimens. The aim of this study therefore is to recruit female patients undergoing IVF with different causes of infertility and age, and harvest granulosa cells from remaining material (follicular aspirates) generated at the time of egg retrieval. Granulosa cells will be cultured in vitro and cellular functions assessed. The investigators will also recruit female patients with normal fertility undergoing IVF procedure due to other reasons (i.e. egg freezing, diagnostics of genetic diseases on embryos).

NCT ID: NCT04472234 Completed - Infertility, Female Clinical Trials

BPA Levels Relationship With IVF/ICSI Outcomes in Unexplained Infertility

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

The relationship between BPA elevation in urine, blood, and follicle fluid and embryo quality, IVF/ICSI outcomes.

NCT ID: NCT04446572 Completed - Clinical trials for Infertility Unexplained

Application of Lactobacillus Salivarius CECT5713 in Infertility of Unknown Origin

Start date: October 16, 2018
Phase: Phase 2
Study type: Interventional

In this study, we aimed to assess the cervicovaginal environment (pH, Nugent score, soluble immune factors and bacterial profile) in women with reproductive failure because of either repetitive abortion or infertility of unknown origin and compare it to that of healthy fertile women. The second objective was to evaluate the ability of Lactobacillus salivarius CECT5713 to modulate such parameters and to increase pregnancy rates in women with reproductive failure. The administration of L. salivarius CECT5713 (~9 log10 colony-forming units (CFU)/day) for 6 months or until a diagnosis of pregnancy to women with reproductive failure resulted in an overall successful (term) pregnancy rate of 56%.

NCT ID: NCT04184323 Withdrawn - Endometriosis Clinical Trials

SIRT-1 Antagonism for Endometrial Receptivity

SAFER
Start date: January 2022
Phase: Phase 2
Study type: Interventional

Progesterone resistance is mediated through epigenetic modification through SirT1 activation and is thought to contribute to infertility and progression of endometriosis. Endometriosis is a leading cause of unexplained IVF failure secondary to inflammatory changes that induce SirT1. The current study is designed to investigate a small molecule inhibitor of SirT1, in the clinical setting of In Vitro Fertilization and Embryo Transfer. The SAFER trial will compare EX-527 to placebo in a randomized, double-blind trial. Primary endpoints include Live Birth Rate (LBR) and secondary outcomes include pregnancy rate (PR), miscarriage rate (MR) and implantation failure rate.